Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study

Autoria(s): O'Dwyer, M.C.; Kent, E.; Parker, M.; Swords, R.T.; Giles, F.; Le Coutre, P.; Padmanabhan, S.; Moulton, B.; McMullin, Mary Frances; Langabeer, S.; Egan, K.; Conneally, E.
Data(s)

01/12/2009
Identificador

http://pure.qub.ac.uk/portal/en/publications/nilotinib-300-mg-twice-daily-is-effective-and-well-tolerated-as-first-line-treatment-of-phpositive-chronic-myeloid-leukemia-in-chronic-phase-preliminary-results-of-the-icorg-0802-phase-2-study(38694ee3-7e57-49c2-97ef-2a979f2a77c4).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

O'Dwyer , M C , Kent , E , Parker , M , Swords , R T , Giles , F , Le Coutre , P , Padmanabhan , S , Moulton , B , McMullin , M F , Langabeer , S , Egan , K & Conneally , E 2009 , ' Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study ' Blood , vol 114 , pp. 1277-1277 .
Tipo

article
Acesso ao item digital